Handok teams up with AmpliMed over promising anticancer drug

Published: 2008-09-12 06:53:00

Updated: 2008-09-12 06:53:00

Handok Pharm announced on September 5 that it has entered into a licensing agreement with the U.S. company AmpliMed for Amplimexon(imexon, inj.), a lead compound for treatment of various cancers.

Under the terms of the agreement, Handok will have an exclusive license to develop and market Ampl...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK